Biohit to partner with Ferring Pharmaceuticals
Biohit Oyj June 24, 2013 at 11:15 A.M. local time (EET)
Finnish healthcare company Biohit has signed a distribution agreement with Ferring Pharmaceuticals Ltd. The agreement gives Biohit the right to sub-distribute Preventis' ‘PreventID® CalScreen®’ rapid test through Ferring to primary healthcare systems in The United Kingdom and the republic of Ireland.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com.
Ferring Pharmaceuticals in brief
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of gastroenterology, reproductive health, urology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products please visit www.ferring.com.
PreventID®CalScreen® - Simple screening test for Faecal Calprotectin in Primary Care
Differential diagnosis of IBD and IBS in patients with chronic bowel problems can be difficult and often involves costly and invasive examinations. The PreventID® CalScreen® from Preventis is an ideal support for Primary Care in the decision when to refer to a specialist gastroenterologist for follow-up: The immunological rapid test determines the inflammation marker calprotectin in stool and distinguishes with a cut-off at 50 μg/g between inflammatory (≥ 50 μg/g) and non-inflammatory (< 50 μg/g) diseases. The test thereby allows a reliable classification of IBD and IBS patients. This discrimination serves as a swift decision aid for further diagnostic procedures in first-line screening of patients with intestinal problems.